Stocks and Investing Stocks and Investing
Wed, November 8, 2017
Tue, November 7, 2017
Mon, November 6, 2017
Fri, November 3, 2017

David Risinger Maintained (TEVA) at Sell with Decreased Target to $7 on, Nov 3rd, 2017


Published on 2024-10-26 00:27:54 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $14 to $7 on, Nov 3rd, 2017.

David has made no other calls on TEVA in the last 4 months.



There are 8 other peers that have a rating on TEVA. Out of the 8 peers that are also analyzing TEVA, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
  • Liav Abraham of "Citigroup" Downgraded from Strong Buy to Hold on, Wednesday, August 16th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017


These are the ratings of the 3 analyists that currently disagree with David


  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Vamil Divan of "JMP Securities" Maintained at Sell with Increased Target to $14 on, Wednesday, September 6th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017